4.3 Review

Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders

Journal

SEMINARS IN NUCLEAR MEDICINE
Volume 45, Issue 1, Pages 58-65

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.semnuclmed.2014.07.008

Keywords

-

Funding

  1. National Cancer Institute, USA [R01-CA111613]
  2. National Institutes of Health, USA

Ask authors/readers for more resources

The use of F-18-sodium fluoride (F-18-NaF) with PET/CT is increasing. This resurgence of an old tracer has been fueled by several factors including superior diagnostic performance over standard Tc-99m-based bone scintigraphy, growth in the availability of PET/CT imaging systems, increase in the number of regional commercial distribution centers for PET radiotracers, the recent concerns about potential recurring shortages with Tc-99m-based radiotracers, and the recent decision by the Centers for Medicare and Medicaid Services to reimburse for F-18-NaF PET/CT for evaluation of patients with known or suspected bone metastases through the National Oncologic PET Registry. The major goal of this article is to review the current evidence on the diagnostic utility of F-18-NaF in the imaging assessment of the bone and joint in a variety of clinical conditions. (C) 2015 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available